Among the 43 patients with analysable plasma samples, 6 (14%) had detectable circulating PIK3CA mutations, corresponding to 6/11 patients (55%) with PIK3CA-mutated tumours and with detectable cfDNA and 0/32 non-mutated tumours. This evidence concerns the gene PIK3CA and neoplasm.